Overview

Clinical Study of R744 to Hemodialysis Patients

Status:
Completed

Trial end date:
2008-08-01

Target enrollment:

Participant gender:

Summary

This study used as the comparative drug (epoetin beta) will assess the efficacy and safety of intravenous injections of R744 in renal anemia patients on Hemodialysis patients.

Phase:

Phase 3

Details

Lead Sponsor:

Chugai Pharmaceutical

Treatments:

Epoetin Alfa